Arginine-Rich Peptide Conjugation to Morpholino Oligomers:  Effects on Antisense Activity and Specificity

Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation...

Full description

Saved in:
Bibliographic Details
Published inBioconjugate chemistry Vol. 16; no. 4; pp. 959 - 966
Main Authors Nelson, Michelle H, Stein, David A, Kroeker, Andrew D, Hatlevig, Susie A, Iversen, Patrick L, Moulton, Hong M
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 01.07.2005
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2−PMO generated antisense activity 3−25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2−PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2−PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations ≤10 μM, only l-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an l- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound.
AbstractList Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2-PMO generated antisense activity 3-25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2-PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2-PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations less than or equal to muM, only L-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an L- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound.[PUBLICATION ABSTRACT]
Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2-PMO generated antisense activity 3-25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2-PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2-PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations < or = 10 microM, only L-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an L- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound.
Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2-PMO generated antisense activity 3-25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2-PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2-PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations less than or equal to 10 mu M, only L-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an L- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound.
Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective means for cellular delivery of PMOs is through their conjugation to arginine-rich peptides. Understanding the effect of peptide conjugation on the efficacy, toxicity, and specificity of PMOs is important to the successful application of this antisense delivery method. We investigated the effects of conjugation of arginine-rich peptides to PMO on the thermal stability, efficacy and specificity for targeted RNA of the resulting compound. In vitro translation assays showed that (1) R9F2−PMO generated antisense activity 3−25-fold higher than corresponding nonconjugated PMO, (2) the level of antisense activity enhancement by R9F2−PMO over a corresponding nonconjugated PMO is related to the GC content of the PMO sequence, (3) R9F2 conjugation reduced the minimum length of a PMO required to inactivate a target RNA from 20 bases to 14 bases, and (4) nonspecific effects of R9F2−PMO occur at lower concentrations than corresponding PMO alone. Thermal stability of heteroduplexes of PMO and complementary RNA were increased by conjugation of PMO to R9F2 peptide, likely accounting for the increased specific antisense activity of conjugated over nonconjugated PMO. A cell-culture based assay demonstrated that while conjugation to unnatural peptides increased PMO efficacy without causing nonspecificity at concentrations ≤10 μM, only l-peptide conjugation retained high specificity at higher concentrations. This study demonstrates that conjugation of PMO to an arginine-rich peptide generally increases the binding affinity of the PMO to complementary RNA and increases its antisense potency. Additionally, it is shown that the enzymatic stability of an l- or unnatural peptide used for PMO conjugation affects the antisense properties of the resulting compound.
Author Nelson, Michelle H
Stein, David A
Iversen, Patrick L
Hatlevig, Susie A
Moulton, Hong M
Kroeker, Andrew D
Author_xml – sequence: 1
  givenname: Michelle H
  surname: Nelson
  fullname: Nelson, Michelle H
– sequence: 2
  givenname: David A
  surname: Stein
  fullname: Stein, David A
– sequence: 3
  givenname: Andrew D
  surname: Kroeker
  fullname: Kroeker, Andrew D
– sequence: 4
  givenname: Susie A
  surname: Hatlevig
  fullname: Hatlevig, Susie A
– sequence: 5
  givenname: Patrick L
  surname: Iversen
  fullname: Iversen, Patrick L
– sequence: 6
  givenname: Hong M
  surname: Moulton
  fullname: Moulton, Hong M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16029037$$D View this record in MEDLINE/PubMed
BookMark eNpl0N1qFDEUB_AgFfuhF76ABEGhF6P5mMlkvNsu1QqVLm1F8CZkMme22c4m0yQj9q63vmafpJFdWtCrJJwfJ-f899GO8w4Qek3JB0oY_dgaUhFKyuoZ2qMVI0UpKdvJd1LygkrCdtF-jCtCSEMle4F2qSCsIbzeQ9ezsLTOOijOrbnCCxiT7QDPvVtNS52sdzh5_M2H8coP1nl8NtilX0OIn-7v_uDjvgeTIs5s5pKN4CLgmUn2l023WLsOX4xgbG9Nfr9Ez3s9RHi1PQ_Q98_Hl_OT4vTsy9f57LTQJWlS0fBWMF0zTYwAqI1ppWasraTo6hJKXmnBeQltTztSV33eJa8siZGUU6hEzQ_Q-03fMfibCWJSaxsNDIN24KeoaM1lyRjN8O0_cOWn4PJsilFBpRCyyehwg0zwMQbo1RjsWodbRYn6G796jD_bN9uGU7uG7klu886g2AAbE_x-rOtwrfLgdaUuFxdqfiLPf_7gC3WU_buN1yY-Dff_xw_36Zwh
CitedBy_id crossref_primary_10_1093_brain_awq002
crossref_primary_10_1016_j_virol_2008_03_032
crossref_primary_10_1039_C3RA45257C
crossref_primary_10_1128_AAC_00644_06
crossref_primary_10_1128_AAC_01286_05
crossref_primary_10_1134_S1068162023060067
crossref_primary_10_1002_0471142727_mb2608s83
crossref_primary_10_1002_iub_297
crossref_primary_10_1021_cr0502448
crossref_primary_10_1002_0471142700_nc0430s27
crossref_primary_10_1039_C4MD00184B
crossref_primary_10_1016_j_cell_2007_09_043
crossref_primary_10_1016_j_jconrel_2012_04_003
crossref_primary_10_1016_j_jconrel_2006_09_011
crossref_primary_10_1016_j_vetmic_2006_06_006
crossref_primary_10_1021_ja060873e
crossref_primary_10_1016_j_tet_2008_11_069
crossref_primary_10_1038_nprot_2007_302
crossref_primary_10_31857_S013234232306009X
crossref_primary_10_1128_AAC_00011_08
crossref_primary_10_1128_JVI_02360_06
crossref_primary_10_1021_acs_orglett_6b03342
crossref_primary_10_1039_c3ra47841f
crossref_primary_10_1007_s00204_021_03184_z
crossref_primary_10_1128_AAC_50_3_984_993_2006
crossref_primary_10_1002_med_21706
crossref_primary_10_3390_polym9050177
crossref_primary_10_1016_j_addr_2015_02_008
crossref_primary_10_3390_molecules14031304
crossref_primary_10_1007_s00705_008_0067_0
crossref_primary_10_1038_nrd3459
crossref_primary_10_1093_jac_dkn221
crossref_primary_10_1016_j_antiviral_2011_04_012
crossref_primary_10_1128_JVI_00557_07
crossref_primary_10_1111_j_1440_1681_2006_04403_x
crossref_primary_10_3390_molecules29112658
crossref_primary_10_1007_s00249_023_01673_w
crossref_primary_10_1002_cpnc_21
crossref_primary_10_1038_onc_2011_300
crossref_primary_10_1128_AAC_00936_08
crossref_primary_10_1128_JVI_00900_06
crossref_primary_10_1089_nat_2013_0449
crossref_primary_10_1016_j_antiviral_2006_05_017
crossref_primary_10_1016_j_medidd_2023_100166
crossref_primary_10_3390_ph3030448
crossref_primary_10_1016_j_tetlet_2008_04_035
Cites_doi 10.1128/JVI.78.11.5891-5899.2004
10.1021/jm0105676
10.1021/bc034221g
10.1128/JVI.79.8.5116-5128.2005
10.1016/j.addr.2004.10.003
10.1089/108729003764097322
ContentType Journal Article
Copyright Copyright © 2005 American Chemical Society
Copyright American Chemical Society Jul/Aug 2005
Copyright_xml – notice: Copyright © 2005 American Chemical Society
– notice: Copyright American Chemical Society Jul/Aug 2005
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7TM
8FD
FR3
P64
DOI 10.1021/bc0501045
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Biotechnology Research Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Nucleic Acids Abstracts
Biotechnology and BioEngineering Abstracts
DatabaseTitleList Engineering Research Database
MEDLINE
Engineering Research Database

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Biology
EISSN 1520-4812
EndPage 966
ExternalDocumentID 878012731
10_1021_bc0501045
16029037
ark_67375_TPS_CH8RZW3P_B
b317947587
Genre Journal Article
Feature
GroupedDBID -
23N
53G
55A
5GY
5VS
7~N
AABXI
ABMVS
ABUCX
ACGFS
ACIWK
ACJ
ACPRK
ACS
AEESW
AENEX
AFEFF
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
ANTXH
AQSVZ
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
IH9
IHE
JG
JG~
LG6
P2P
PQEST
PQQKQ
ROL
TN5
TWZ
UI2
VF5
VG9
W1F
X
XKZ
YZZ
---
-~X
4.4
ABFRP
ABJNI
ABQRX
ADHLV
AHGAQ
BSCLL
GGK
1WB
AALRI
AAXUO
ABHMW
AGXLV
BAANH
CGR
CUPRZ
CUY
CVF
ECM
EIF
FDB
NPM
RNS
AAYXX
CITATION
7QO
7TM
8FD
FR3
P64
ID FETCH-LOGICAL-a409t-93b62a72a0c6ee7ccb8a22b586d74e435a6334ebf1d075f16052080c8131e5673
IEDL.DBID ACS
ISSN 1043-1802
IngestDate Thu Aug 15 22:30:32 EDT 2024
Fri Sep 13 02:47:22 EDT 2024
Fri Aug 23 00:39:08 EDT 2024
Sat Sep 28 07:45:22 EDT 2024
Wed Jan 17 04:51:43 EST 2024
Thu Aug 27 13:42:48 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a409t-93b62a72a0c6ee7ccb8a22b586d74e435a6334ebf1d075f16052080c8131e5673
Notes ark:/67375/TPS-CH8RZW3P-B
istex:05984FB69C031BA5593673E167788B56AD34B3F0
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 16029037
PQID 216186689
PQPubID 45565
PageCount 8
ParticipantIDs proquest_miscellaneous_17384221
proquest_journals_216186689
crossref_primary_10_1021_bc0501045
pubmed_primary_16029037
istex_primary_ark_67375_TPS_CH8RZW3P_B
acs_journals_10_1021_bc0501045
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
XKZ
7~N
ACJ
VG9
W1F
ANTXH
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 2005-07-01
PublicationDateYYYYMMDD 2005-07-01
PublicationDate_xml – month: 07
  year: 2005
  text: 2005-07-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle Bioconjugate chemistry
PublicationTitleAlternate Bioconjugate Chem
PublicationYear 2005
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Stein D. (bc0501045b00015/bc0501045b00015_1) 1997
Arora V. (bc0501045b00004/bc0501045b00004_1) 2002; 91
Summerton J. E. (bc0501045b00005/bc0501045b00005_1) 2003
Neuman B. W. (bc0501045b00010/bc0501045b00010_1) 2005
Kinney R. M. (bc0501045b00012/bc0501045b00012_1) 2005; 79
Summerton J. (bc0501045b00001/bc0501045b00001_1) 1997
Rothbard J. B. (bc0501045b00017/bc0501045b00017_1) 2002; 45
bc0501045b00008/bc0501045b00008_1
Rothbard J. B. (bc0501045b00018/bc0501045b00018_1) 2005; 57
Summerton J. (bc0501045b00002/bc0501045b00002_1) 1999; 1489
Hudziak R. M. (bc0501045b00003/bc0501045b00003_1) 1996
Moulton H. M. (bc0501045b00007/bc0501045b00007_1) 2003; 13
Kang S. H. (bc0501045b00014/bc0501045b00014_1) 1998
Deas T. S. (bc0501045b00011/bc0501045b00011_1) 2005; 79
Corey D. R. (bc0501045b00016/bc0501045b00016_1) 1995; 117
Neuman B. W. (bc0501045b00009/bc0501045b00009_1) 2004; 78
Ghosh C. (bc0501045b00006/bc0501045b00006_1) 2000
Summerton J. (bc0501045b00013/bc0501045b00013_1) 1991
References_xml – volume-title: Uncharged morpholino-based polymers having phosphorus containing chiral intersubunit linkages. U.S. Patent 5185444
  year: 1991
  ident: bc0501045b00013/bc0501045b00013_1
  contributor:
    fullname: Summerton J.
– volume: 117
  year: 1995
  ident: bc0501045b00016/bc0501045b00016_1
  publication-title: J. Am. Chem. Soc.
  contributor:
    fullname: Corey D. R.
– year: 2005
  ident: bc0501045b00010/bc0501045b00010_1
  publication-title: J. Virol., in press.
  contributor:
    fullname: Neuman B. W.
– volume-title: Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules
  year: 2003
  ident: bc0501045b00005/bc0501045b00005_1
  contributor:
    fullname: Summerton J. E.
– volume: 78
  year: 2004
  ident: bc0501045b00009/bc0501045b00009_1
  publication-title: J. Virol.
  doi: 10.1128/JVI.78.11.5891-5899.2004
  contributor:
    fullname: Neuman B. W.
– volume: 45
  year: 2002
  ident: bc0501045b00017/bc0501045b00017_1
  publication-title: J. Med. Chem.
  doi: 10.1021/jm0105676
  contributor:
    fullname: Rothbard J. B.
– volume-title: Morpholino antisense oligomers:  design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187−195
  year: 1997
  ident: bc0501045b00001/bc0501045b00001_1
  contributor:
    fullname: Summerton J.
– ident: bc0501045b00008/bc0501045b00008_1
  doi: 10.1021/bc034221g
– volume: 79
  year: 2005
  ident: bc0501045b00012/bc0501045b00012_1
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.8.5116-5128.2005
  contributor:
    fullname: Kinney R. M.
– volume: 91
  year: 2002
  ident: bc0501045b00004/bc0501045b00004_1
  publication-title: J. Pharm. Sci.
  contributor:
    fullname: Arora V.
– volume: 57
  year: 2005
  ident: bc0501045b00018/bc0501045b00018_1
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2004.10.003
  contributor:
    fullname: Rothbard J. B.
– volume-title: DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7, 151−157.
  year: 1997
  ident: bc0501045b00015/bc0501045b00015_1
  contributor:
    fullname: Stein D.
– volume-title: Evaluation of antisense mechanisms of action. Methods Enzymol. 313, 135−143
  year: 2000
  ident: bc0501045b00006/bc0501045b00006_1
  contributor:
    fullname: Ghosh C.
– volume: 1489
  year: 1999
  ident: bc0501045b00002/bc0501045b00002_1
  publication-title: Biochim. Biophys. Acta
  contributor:
    fullname: Summerton J.
– volume: 79
  year: 2005
  ident: bc0501045b00011/bc0501045b00011_1
  publication-title: J. Virol.
  contributor:
    fullname: Deas T. S.
– volume-title: Up-regulation of luciferase gene expression with antisense oligonucleotides:  implications and applications in functional assay development. Biochemistry 37, 6235−6239
  year: 1998
  ident: bc0501045b00014/bc0501045b00014_1
  contributor:
    fullname: Kang S. H.
– volume: 13
  start-page: 43
  year: 2003
  ident: bc0501045b00007/bc0501045b00007_1
  publication-title: Antisense Nucleic Acid Drug Dev.
  doi: 10.1089/108729003764097322
  contributor:
    fullname: Moulton H. M.
– volume-title: Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267−272
  year: 1996
  ident: bc0501045b00003/bc0501045b00003_1
  contributor:
    fullname: Hudziak R. M.
SSID ssj0009182
Score 2.0798957
Snippet Noncharged antisense compounds, such as phosphorodiamidate morpholino oligomers (PMOs), do not readily enter mammalian cells in culture. A simple and effective...
SourceID proquest
crossref
pubmed
istex
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 959
SubjectTerms Amino acids
Arginine - chemistry
Base Sequence
DNA Primers
Enzyme Stability
HeLa Cells
Humans
Morpholines - chemistry
Oligonucleotides, Antisense - chemistry
Oligonucleotides, Antisense - pharmacology
Peptides
Peptides - chemistry
Polymers
Ribonucleic acid
RNA
Title Arginine-Rich Peptide Conjugation to Morpholino Oligomers:  Effects on Antisense Activity and Specificity
URI http://dx.doi.org/10.1021/bc0501045
https://api.istex.fr/ark:/67375/TPS-CH8RZW3P-B/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/16029037
https://www.proquest.com/docview/216186689/abstract/
https://search.proquest.com/docview/17384221
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELZKKwQXKC2PUCgWoN7Sxo84Drd0oVohFVa0FRWXyK-sYCFBu1mJcuLK3-SX4HE2u0KlcIsUR3E8E83Y8833IfScWSttCqIZibUxJ5rFMudZbHTFcq0qzSroRj5-I4Zn_PV5er6Gnl1RwafkQJskhU1Deg1tUEAOQv4zOFkx6xLZlTSBa1MCXGfz0qMQeszsj9CzAav47eq8MsSXo9voZd-l08FKJvvzVu-b75dJG_819U10a5Ff4qJziDtozdVbaLuo_d76ywXewwHxGY7St9D1w_7qxqDXfdtGk2I6BtUIF0PTPR4B7MU6PGjqT_NxsCNuG3zceAOB4E-D337-OG7g-PvFrx8_cUeHPMN-WFGD0nM9c7gwnUgFVrXFQfIeiCvai7vo7OjV6WAYLyQZYuU3gm2cMy2oyqhKjHAuM0ZLRalOpbAZdz71UoIx7nRFrM9FKiIAZiMTIwkjLhUZu4fW66Z2DxBOcitIJUmiJOeO0tzySiso_JnMKc0jtOttVi5-qVkZquWUlMtFjdDT3pzl146a42-D9oKhlyPUdAJYtiwtT0cn5WAo3314z0blYYR2ek9YvZMGOQEh8wg9Wd715oCiiqpdM_fTypjklJII3e_cZzUXkdA8YdnD_33IDroZCGEDCPgRWm-nc_fYpzqt3g2u_htLw_V1
link.rule.ids 315,786,790,2782,27109,27957,27958,57093,57143
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LbtQwFLWgFSobKC2PUGgthLpLiR-xHXbTiGqAThkxU1GxifzKCAaSapKRgBVbfpMvwXbmIV6CXaI4yY2vI9_re3wOAI-JMcKkXjQjMSamSJFYZJTHWpUkU7JUpPS7kQdnrH9OX1ykFwuaHL8XxhnRuCc1oYi_ZhdAT5ROUp87pFfBZspdHu7DoHy0JthFoqtsespN4VE727_d6mcg3fw0A236zvz09_AyTDMnNzu9omBgQJdMj-atOtJffuFu_L8v2AY3FtEm7HXD4xa4YqsdsNurXKb98TM8hAH_GRbWd8C14-XRVr5UgdsF095s4jUkbOy34MOhB8EYC_O6ej-fBK_CtoaD2rnLy__U8NWHd5PaL4Y__f71G-zIkRvomvUqr_tcNRb2dCdZAWVl4OjSBligO78Nzk-ejfN-vBBoiKVLC9s4I4phybFMNLOWa62ExFilghlOrQvEJCOEWlUi4yKTEjEPuhGJFoggmzJO7oCNqq7sPQCTzDBUCpRIQanFODO0VNKXATW3UtEI7Ls-LRY_WFOE2jlGxapTI_Bo6dXisiPq-FOjw-DvVQs5m3pkG0-L8XBU5H3x-u0bMiyOI7C3HBDrd-IgLsBEFoGD1VXnDl9ikZWt584sTgTFGEXgbjeK1rawBGcJ4ff_9SEHYKs_HpwWp8_PXu6B64EqNsCDH4CNdja3D10Q1Kr9MPp_AHUC_eA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagFZQLlJbHUmgthHpLie3EcbilgdXyaLtiW7XiEtmxsyoLyWqTlYATV_4mvwSPk90VL8EtUZxk7LHlGc838yH0hGktdAikGb7WXkAU80QcRF6uChYrWShWQDby0TEfnAWvLsKLzlGEXBgrRG2_VLsgPqzqqS66CgPkqcr9EPyH8CpaD4G4G0yhdLQqsktEG92EspsCkDubv70Ku1Be_7QLrcOAfvq7iem2mv4tdLIU0iFMJgfzRh3kX36p3_j_vdhENzurEyftNLmNrphyC20npfW4P37G-9jhQN0B-xa6dri42kgXbHDbaJLMxsAlYTxIxcdDAMNog9OqfD8fO-3ipsJHlVUb0ABV-OTD5biCQ_Fn379-w22R5BrbZkkJ_M9lbXCSt9QVWJYaj6bGwQPt_R101n9xmg68jqjBk9Y9bLyYKU5lRKWfc2OiPFdCUqpCwXUUGGuQSc5YYFRBtLVQCsIBfCP8XBBGTMgjdhetlVVp7iPsx5qTQhBfiiAwlMY6KJSEcGAeGamCHtq145p1C63OXAydkmw5qD30eKHZbNoW7PhTo32n82ULOZsAwi0Ks9PhKEsH4u27czbMDntoZzEpVv-kjmSAi7iH9pZPrTog1CJLU82tWBETAaWkh-61M2klC_dp7LPowb86soeuD5_3szcvj1_voBuuYqxDCT9Ea81sbh5ZW6hRu24B_AC1CgBp
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Arginine-rich+peptide+conjugation+to+morpholino+oligomers%3A+effects+on+antisense+activity+and+specificity&rft.jtitle=Bioconjugate+chemistry&rft.au=Nelson%2C+Michelle+H&rft.au=Stein%2C+David+A&rft.au=Kroeker%2C+Andrew+D&rft.au=Hatlevig%2C+Susie+A&rft.date=2005-07-01&rft.issn=1043-1802&rft.volume=16&rft.issue=4&rft.spage=959&rft_id=info:doi/10.1021%2Fbc0501045&rft_id=info%3Apmid%2F16029037&rft.externalDocID=16029037
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-1802&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-1802&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-1802&client=summon